Medbox, Inc. (OTCQB:MDBX) (www.medbox.com), a leading dispensary infrastructure/licensing specialist, patented technology provider, and partner to the cannabis industry, announced today that Ambassador Ned L. Siegel (Ret.), Chairman of its Board of Directors, has invested $50,000 in Medbox through the issuance of a convertible loan.
Ambassador Siegel stated, “I believe that Medbox is in a unique position in the cannabis industry to advise investors and entrepreneurs as to how to obtain the required licenses to operate, and subsequently how to manage their businesses with the highest levels of safety, security, profitability and best practices. My investment in the company reflects my confidence that Medbox can build on its market positioning to generate sustainable and profitable revenue growth.”
About Medbox, Inc.
Medbox, Inc. (“MDBX” or the “Company”) is
the leading dispensary infrastructure and licensing specialist, patented
technology provider, and partner to the cannabis industry. Headquartered
in Los Angeles, CA, Medbox, through its wholly owned subsidiary,
Medicine Dispensing Systems, offers its patented systems, software and
consulting services to pharmacies, alternative medicine dispensaries and
local governments in the U.S. In addition, through its wholly owned
subsidiary, Vaporfection International, Inc. (www.vaporfection.com),
the company offers an industry award winning medical line of vaporizer
products. Medbox, through its newly established subsidiaries, is also
developing ancillary services tailored to the alternative medicine
industry, including real estate acquisitions and subsequent lease
programs to alternative medicine dispensaries and cultivation centers,
and alternative medicine dispensary and cultivation management services.
Forward-Looking Statements
The statements in this press
release constitute forward-looking statements within the meaning of
federal securities laws. Such statements are based on our current
beliefs and expectations and are inherently subject to significant
business, economic and competitive uncertainties and contingencies, many
of which are beyond our control. In addition, such forward-looking
statements are subject to assumptions with respect to future business
strategies and decisions that are subject to change. Potential risks and
uncertainties include, but are not limited to, technical advances in the
industry as well as political and economic conditions present within the
industry. We do not take any obligation to update any forward-looking
statement to reflect events or developments after a forward looking
statement was made.
Contact Information
Investor Relations:
Stephen Hart
Hayden IR
917-658-7878
hart@haydenir.com
Medbox:
For more information on Medbox, please call (800) 762-1452.
Contacts:
Investor Relations:
Stephen Hart, 917-658-7878
hart@haydenir.com